Novo Nordisk, a leading Danish pharmaceutical company, has completed a significant acquisition of Ziylo, a biotechnology spin-out from the University of Bristol, for a deal potentially worth over $800 million. This acquisition grants Novo Nordisk full rights to Ziylo’s innovative glucose binding molecules, crucial for the development of glucose responsive insulins. Strategic Importance of the […]
Check out the news story on insulin aspart injection Fiasp FDA approval of the Novo Nordisk insulin product for diabetes treatment in adult patients in the US.
Novo Nordisk, a leading Danish pharmaceutical company, has secured a significant regulatory milestone with the US FDA approval of its innovative fast-acting mealtime insulin aspart injection, Fiasp 100 Units/mL, for diabetes treatment in adults. This approval positions Fiasp as a key player in the diabetes care market in the United States, building on its existing […]
Novo Nordisk’s diabetes medication, Victoza (liraglutide), has gained U.S. Food and Drug Administration (FDA) approval for an expanded use, marking a significant step forward in the treatment of cardiovascular diseases among type 2 diabetes patients. This latest approval allows Victoza to be used to reduce the risk of major adverse cardiovascular events (MACE), including cardiovascular […]
Novo Nordisk diabetes drug Victoza (liraglutide) has been approved by the US FDA for treating major cardiovascular diseases associated with type 2 diabetes.
In a significant advancement for diabetes care, Danish pharmaceutical giant Novo Nordisk has received approval from the U.S. Food and Drug Administration (FDA) to use its diabetes drug Victoza (liraglutide) for treating heart diseases associated with type 2 diabetes. This approval marks a pivotal expansion of Victoza’s usage, positioning it as a key player in […]